预约演示
更新于：2025-08-12
Amoxicillin/Clavulanate Potassium
阿莫西林/克拉维酸钾
更新于：2025-08-12
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H28KN4O10S |
InChIKeyVKJFJOFNYVFTRZ-ZVDZYBSKSA-N |
CAS号74469-00-4 |
关联
254
项与 阿莫西林/克拉维酸钾 相关的临床试验CTR20251228
阿莫西林克拉维酸钾干混悬剂在健康受试者中的人体生物等效性研究
NCT06850714
Evaluation of the Use of Bifidobacterium Breve PRL2020 in Preventing Side Effects From Amoxicillin or Amoxicillin/Clavulanic Acid Antibiotic Use: A Randomized Controlled Trial
NCT06709196
REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.
100 项与 阿莫西林/克拉维酸钾 相关的临床结果
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的转化医学
登录后查看更多信息
100 项与 阿莫西林/克拉维酸钾 相关的专利（医药）
登录后查看更多信息
4,694
项与 阿莫西林/克拉维酸钾 相关的文献（医药）2025-12-31Gut Microbes Reports
Characterization of an Indigenous Lytic Phage Targeting Multidrug-Resistant
Salmonella enterica
作者: Emencheta, Stephen ; Akpa, Paul ; Eze, Emmanuel ; Onuigbo, Ebele ; Obeta, Chinonye ; Attama, Anthony
Multidrug-resistant pathogens have prompted the use of lytic bacteriophages.An indigenous novel lytic bacteriophage against Salmonella enterica strains from environmental wastewater was isolated and characterized using phage survivability study, adsorption curve, one-step curve, optimal multiplicity of infection, and phage-killing assay.The Salmonella strains CP90 and CP23 isolated from the same source were biochem. and molecularly characterized.The Salmonella strains CP90 and CP23 had 96.24% and 97.18% pairwise identity resp. with S. enterica.Both were resistant to B-lactam Aminoglycosides, Penicillin, and Phenicol class of antibiotics.The phage performed better in an alk. medium and below 50°C.About 80% of the phage had an adsorption rate of 12 min and a latent period of 20 min.About 55 PFU/cell of the phage was released during a single replication cycle, inhibiting bacteria growth for up to 5 h.The characterization of this indigenous phage suggests its therapeutic potential against multidrug-resistant Salmonella species.
2025-09-01INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY
Endoscopic-guided cultures in pediatric recurrent acute rhinosinusitis
Article
作者: Meashi, Hassan M ; Alshomrani, Mohammad K ; Almazrou, Rana K ; Almazrou, Khalid A ; Alkhudiri, Nourah A
BACKGROUND:
Rhinosinusitis is a highly prevalent disease among children. Many pathogens cause acute bacterial rhinosinusitis; however, literature is scarce when it comes to identifying bacteria responsible for pediatric recurrent acute rhinosinusitis (PRARS). This study aims to identify the most common organisms causing PRARS along with antimicrobial susceptibility, ideally with an endoscopic-guided culture from the middle meatus.
METHODS:
Retrospective data were collected between 2017 and 2023 for all PRARS patients who attended a pediatric ENT clinic at a tertiary hospital. Demographic characteristics and clinical data of 109 children were gathered. Samples were obtained through endoscopic-guided middle meatal cultures under general anesthesia.
RESULTS:
Cultures were positive in 56 patients (51.4 %) consisting of either one or more organisms. The incidence of positive bacterial cultures was higher in the post-Covid19 era (74 versus 35). The predominant solo organism isolated was Moraxella species, accounting for 31.8 % of the total positive cultures. The second most common organism was Haemophilus influenzae (21.2 %). Staphylococcus aureus (18.2 %) was the third most isolated organism. Almost all Moraxella isolates were sensitive to amoxicillin-clavulanic acid, macrolides, and cefuroxime (100 %, 100 %, and 95 %, respectively). All Haemophilus isolates were 100 % sensitive to ceftriaxone and levofloxacin. All Streptococcus pneumoniae isolates were 100 % sensitive to penicillin and levofloxacin.
CONCLUSION:
In PRARS, endoscopic-guided middle meatal cultures provided an accurate identification of the causative organism. A culture directed antibiotic choice will lead to a more favorable medical outcome.
2025-08-01JOURNAL OF PHARMACEUTICAL SCIENCES
Disintegration-dissolution modeling of bilayer tablets: Predicting plasma profiles and antimicrobial efficacy under postprandial conditions
Article
作者: Kinzig, Martina ; Horkovics-Kovats, Stefan ; Sörgel, Fritz ; Federič, Jozef
This study presents the application of the Disintegration-Dissolution Model (DDM) as a first-principle approach for analyzing and predicting dissolution profiles of complex tablet formulations, such as Augmentin XR, which consists of two layers with distinct disintegration characteristics. The DDM successfully extracted disintegration kinetics from dissolution time profiles and was validated by comparison with independent magnetic moment measurements. Additionally, the study integrates the DDM with a Stomach Absorption Window (DDM-SAW) model to enhance pharmacokinetic predictions for amoxicillin and clavulanic acid under in vivo conditions. Monte Carlo simulations used to assess efficacy of amoxicillin treatment across different dosing scenarios, provide valuable insights into the impact of dosing regimens on therapeutic outcomes. The DDM-SAW model also facilitates dose balance calculations, offering detailed information about the bioavailability of amoxicillin released from individual tablet layers. The results demonstrate that the DDM-SAW model can be a useful tool to enable formulation optimization, improve the understanding of dissolution and absorption processes, and predict pharmacokinetics. The study highlights the potential of model-based analysis in drug development and optimization, especially for complex formulations with multiple components and distinct dissolution behaviors.
100 项与 阿莫西林/克拉维酸钾 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨和关节感染 | 加拿大 | 2020-01-28 | |
| 妇科疾病 | 加拿大 | 2020-01-28 | |
| 腹腔感染 | 加拿大 | 2020-01-28 | |
| 严重感染 | 加拿大 | 2020-01-28 | |
| 皮肤结构和软组织感染 | 加拿大 | 2020-01-28 | |
| 急性细菌性鼻窦炎 | 美国 | 2002-09-25 | |
| 慢性支气管炎 | 澳大利亚 | 1998-01-08 | |
| 社区获得性肺炎 | 澳大利亚 | 1998-01-08 | |
| 急性支气管炎 | 日本 | 1988-08-01 | |
| 咽炎 | 日本 | 1988-08-01 | |
| 扁桃体炎 | 日本 | 1988-08-01 | |
| 膀胱炎 | 日本 | 1985-07-29 | |
| 淋病 | 日本 | 1985-07-29 | |
| 子宫内感染 | 日本 | 1985-07-29 | |
| 淋巴结炎 | 日本 | 1985-07-29 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 日本 | 1985-07-29 | |
| 肾盂肾炎 | 日本 | 1985-07-29 | |
| 脓皮症 | 日本 | 1985-07-29 | |
| 慢性呼吸道感染 | 日本 | 1985-07-29 | |
| 细菌感染 | 美国 | 1985-07-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性鼻窦炎 | 临床3期 | 日本 | 2013-08-30 | |
| 急性肾盂肾炎 | 临床2期 | 中国 | 2023-02-10 | |
| 化脓 | 临床2期 | 中国 | 2015-05-19 | |
| 泌尿系统感染 | 临床2期 | 中国 | 2013-05-15 | |
| 化脓性扁桃体炎 | 临床2期 | 中国 | 2013-05-15 | |
| 急性中耳炎 | 临床1期 | 中国 | 2024-04-22 | |
| 蜂窝织炎 | 临床1期 | 中国 | 2024-04-22 | |
| 骨髓炎 | 临床1期 | 中国 | 2024-04-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 66 | Clinically directed initiation of amoxicillin-clavulanate | 襯鑰膚醖鏇網餘艱糧憲(簾蓋餘顧獵積廠範鹹憲) = 壓鹽範窪夢齋膚鬱鹽繭 憲淵選願襯衊糧構選積 (淵夢繭選選膚艱觸遞艱 ) | 不佳 | 2025-06-23 | ||
Routine use of amoxicillin-clavulanate | 襯鑰膚醖鏇網餘艱糧憲(簾蓋餘顧獵積廠範鹹憲) = 簾淵構鑰鬱淵範築壓鏇 憲淵選願襯衊糧構選積 (淵夢繭選選膚艱觸遞艱 ) 更多 | ||||||
早期临床1期 | 118 | (Concurrent BB-12 Yogurt and Amoxicillin-clavulanate) | 積鬱願襯構鹹淵鬱廠網(醖餘鏇範製選淵繭繭蓋) = 顧壓範餘顧鏇糧構壓廠 繭鬱願鏇製蓋願積遞壓 (觸蓋顧齋廠網餘齋窪鬱, 糧築範鹽簾鬱獵鹹膚製 ~ 廠廠範夢齋蓋選糧膚遞) 更多 | - | 2025-02-25 | ||
(BB-12 Yogurt Taken 4 Hours After Amoxicillin-clavulanate) | 積鬱願襯構鹹淵鬱廠網(醖餘鏇範製選淵繭繭蓋) = 鬱獵夢範網範遞顧遞鬱 繭鬱願鏇製蓋願積遞壓 (觸蓋顧齋廠網餘齋窪鬱, 憲鹽網鬱範醖膚餘顧壓 ~ 壓膚衊糧構構艱蓋積淵) 更多 | ||||||
临床2期 | 3 | (Standard Perioperative Antibiotics) | 壓顧淵製壓襯選艱糧願(選遞蓋壓膚觸選遞憲糧) = 蓋鹽窪餘鹽構蓋蓋膚鹽 獵夢願廠觸鏇鏇願簾壓 (鹹夢餘齋構構窪蓋膚構, 鑰鬱膚窪蓋鏇遞選糧醖 ~ 淵壓繭膚鑰獵積顧觸築) 更多 | - | 2024-09-24 | ||
(Extended Antibiotic Prophylaxis) | 遞構繭鑰簾選壓鹹膚鏇 = 簾鏇選齋夢積顧鑰簾獵 餘衊蓋壓艱簾觸築廠鏇 (簾淵鏇構蓋夢夢艱壓簾, 淵襯繭蓋齋襯衊淵膚膚 ~ 餘築齋獵鑰鏇願窪壓構) 更多 | ||||||
N/A | - | 6,207 | 顧製鑰顧顧窪獵衊壓鹽(構廠構積顧壓壓膚選壓) = 構襯窪憲鹽觸製艱廠鏇 願襯網繭範製蓋鑰廠簾 (築範構衊餘衊膚鏇壓餘 ) | 积极 | 2023-09-25 | ||
顧製鑰顧顧窪獵衊壓鹽(構廠構積顧壓壓膚選壓) = 齋範構膚構觸願顧醖鏇 願襯網繭範製蓋鑰廠簾 (築範構衊餘衊膚鏇壓餘 ) | |||||||
临床2期 | 112 | (Rifampin Resistant A) | 鬱範壓齋選獵齋夢簾網(顧範遞鏇鏇繭窪選糧壓) = 鹹鹽窪鏇鹽選糧願齋觸 鹹網繭遞齋觸齋淵製鹽 (餘齋鏇簾鑰窪鹹願廠夢, 糧選鏇製觸淵齋憲憲鑰 ~ 簾鏇鹹膚衊衊衊壓觸簾) 更多 | - | 2023-07-19 | ||
(Rifampin Resistant B) | 鬱範壓齋選獵齋夢簾網(顧範遞鏇鏇繭窪選糧壓) = 積網淵鏇糧鹽鏇簾鬱鬱 鹹網繭遞齋觸齋淵製鹽 (餘齋鏇簾鑰窪鹹願廠夢, 遞獵製廠選淵製壓築積 ~ 糧蓋衊築範壓製鏇壓鹹) 更多 | ||||||
临床3期 | 515 | (Amoxicillin-clavulanate) | 願艱製鬱淵範鬱壓糧膚(觸鹹積廠淵窪積顧獵艱) = 網壓齋蓋壓築齋艱襯遞 遞鬱膚齋夢積齋襯醖廠 (願遞鹹範壓簾獵蓋餘鏇, 7.8) 更多 | - | 2023-06-08 | ||
Placebo (Placebo) | 願艱製鬱淵範鬱壓糧膚(觸鹹積廠淵窪積顧獵艱) = 壓積艱窪膚醖簾鏇顧範 遞鬱膚齋夢積齋襯醖廠 (願遞鹹範壓簾獵蓋餘鏇, 7.6) 更多 | ||||||
临床2期 | 60 | (Pathological Phenotype) | 觸淵膚構鑰積齋觸窪廠(淵網憲夢齋窪壓夢製繭) = 顧膚選鏇鏇醖齋衊蓋製 餘醖壓獵窪鬱醖鏇鏇積 (廠憲構築蓋繭範壓壓範, 壓餘積艱糧壓壓鏇鏇餘 ~ 築鹽願網製齋遞觸壓艱) 更多 | - | 2023-03-06 | ||
(Clinical Guidelines) | 觸淵膚構鑰積齋觸窪廠(淵網憲夢齋窪壓夢製繭) = 艱製齋淵壓衊夢膚廠遞 餘醖壓獵窪鬱醖鏇鏇積 (廠憲構築蓋繭範壓壓範, 衊蓋鏇鏇顧夢顧壓壓憲 ~ 壓窪鬱構壓膚鬱繭襯觸) 更多 | ||||||
N/A | 82 | peripheral inserted central Catheter+home intravenous ertapenem (Home Intravenous Ertapenem and PICC) | 憲顧襯淵觸鹽鏇壓淵膚 = 遞範願獵艱獵艱簾襯蓋 衊鑰餘淵鏇鹹糧遞艱夢 (餘積夢夢選淵糧齋膚簾, 顧艱遞襯範糧齋膚積憲 ~ 簾選憲顧淵壓網觸艱壓) 更多 | - | 2022-03-23 | ||
(Home Oral Amoxicillin-clavulanate) | 憲顧襯淵觸鹽鏇壓淵膚 = 鏇繭簾齋鏇遞窪鹽艱膚 衊鑰餘淵鏇鹹糧遞艱夢 (餘積夢夢選淵糧齋膚簾, 鏇構醖醖餘積襯觸壓觸 ~ 淵夢選觸繭壓襯鏇簾糧) 更多 | ||||||
临床3期 | 284 | Prednisolone plus antibiotics | 壓夢夢衊獵願齋鹽範廠(選糧簾鏇鬱製糧餘糧鹽) = 遞積糧廠鹹遞遞衊蓋選 鬱鬱夢鹽糧蓋窪襯獵遞 (願積糧範鹽膚夢鑰製繭 ) 更多 | 不佳 | 2021-06-23 | ||
Prednisolone plus placebo | 壓夢夢衊獵願齋鹽範廠(選糧簾鏇鬱製糧餘糧鹽) = 鹽繭鑰鑰築鏇選遞構廠 鬱鬱夢鹽糧蓋窪襯獵遞 (願積糧範鹽膚夢鑰製繭 ) 更多 | ||||||
临床4期 | 385 | (Short Course) | 淵艱窪衊願艱選廠製窪: Pr (Higher DOOR in Short-Course) = 0.69 (95% CI, 0.63 ~ 0.75), P-Value = <0.001 更多 | - | 2021-02-03 | ||
(Standard Course) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用